Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody

Ronit Rosenfeld (), Tal Noy-Porat, Adva Mechaly, Efi Makdasi, Yinon Levy, Ron Alcalay, Reut Falach, Moshe Aftalion, Eyal Epstein, David Gur, Theodor Chitlaru, Einat B. Vitner, Sharon Melamed, Boaz Politi, Ayelet Zauberman, Shirley Lazar, Adi Beth-Din, Yentl Evgy, Shmuel Yitzhaki, Shmuel C. Shapira, Tomer Israely and Ohad Mazor ()
Additional contact information
Ronit Rosenfeld: Israel Institute for Biological Research
Tal Noy-Porat: Israel Institute for Biological Research
Adva Mechaly: Israel Institute for Biological Research
Efi Makdasi: Israel Institute for Biological Research
Yinon Levy: Israel Institute for Biological Research
Ron Alcalay: Israel Institute for Biological Research
Reut Falach: Israel Institute for Biological Research
Moshe Aftalion: Israel Institute for Biological Research
Eyal Epstein: Israel Institute for Biological Research
David Gur: Israel Institute for Biological Research
Theodor Chitlaru: Israel Institute for Biological Research
Einat B. Vitner: Israel Institute for Biological Research
Sharon Melamed: Israel Institute for Biological Research
Boaz Politi: Israel Institute for Biological Research
Ayelet Zauberman: Israel Institute for Biological Research
Shirley Lazar: Israel Institute for Biological Research
Adi Beth-Din: Israel Institute for Biological Research
Yentl Evgy: Israel Institute for Biological Research
Shmuel Yitzhaki: Israel Institute for Biological Research
Shmuel C. Shapira: Israel Institute for Biological Research
Tomer Israely: Israel Institute for Biological Research
Ohad Mazor: Israel Institute for Biological Research

Nature Communications, 2021, vol. 12, issue 1, 1-9

Abstract: Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), exhibits high levels of mortality and morbidity and has dramatic consequences on human life, sociality and global economy. Neutralizing antibodies constitute a highly promising approach for treating and preventing infection by this novel pathogen. In the present study, we characterize and further evaluate the recently identified human monoclonal MD65 antibody for its ability to provide protection against a lethal SARS-CoV-2 infection of K18-hACE2 transgenic mice. Eighty percent of the untreated mice succumbed 6–9 days post-infection, while administration of the MD65 antibody as late as 3 days after exposure rescued all infected animals. In addition, the efficiency of the treatment is supported by prevention of morbidity and ablation of the load of infective virions in the lungs of treated animals. The data demonstrate the therapeutic value of human monoclonal antibodies as a life-saving treatment for severe COVID-19 infection.

Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-21239-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-21239-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-21239-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().